Swiss National Bank Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Swiss National Bank boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 117,800 shares of the company’s stock after buying an additional 3,000 shares during the quarter. Swiss National Bank owned 0.12% of Day One Biopharmaceuticals worth $1,493,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of DAWN. R Squared Ltd purchased a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $31,000. Quest Partners LLC boosted its stake in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after buying an additional 7,668 shares during the last quarter. E Fund Management Co. Ltd. bought a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth $143,000. Dynamic Technology Lab Private Ltd bought a new position in Day One Biopharmaceuticals in the third quarter valued at about $174,000. Finally, XTX Topco Ltd purchased a new position in Day One Biopharmaceuticals in the third quarter worth about $178,000. Institutional investors own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Bank of America lowered their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. The Goldman Sachs Group dropped their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday. HC Wainwright reduced their price objective on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Wedbush reiterated an “outperform” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $32.29.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, CEO Jeremy Bender sold 12,048 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,064 shares of company stock valued at $251,925 in the last three months. 8.40% of the stock is currently owned by corporate insiders.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $8.07 on Friday. The stock has a fifty day simple moving average of $10.60 and a two-hundred day simple moving average of $12.61. The firm has a market capitalization of $817.93 million, a PE ratio of -7.83 and a beta of -1.38. Day One Biopharmaceuticals, Inc. has a 52-week low of $7.88 and a 52-week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million. On average, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.